Patient and treatment characteristics
| UPN . | Age/sex . | Status at allo SCT . | β2M (mg/L) . | Conditioning . | GVHD prophylaxis . | Source of SC . | GVHD . | Time to CR, mo . | Survival, mo . | Latest disease status . | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute . | Chronic . | ||||||||||
| 15 | 35/F | Resp | 1.7 | TBI + Cy + MEL | CsA | BM | 1 | limited | 12 | 188+ | CR |
| 95 | 49/F | Resp | 1.9 | BU-Cy 4 | T depletion | BM | 0 | none | 3 | 98+ | CR |
| 116 | 37/F | Resp | 2.1 | BU-Cy 4 | CsA + MTX | BM | 1 | limited | 3 | 84+ | CR |
| 142 | 36/F | Resp | 1.4 | BU-Cy 4 | CsA + MTX | BM | 0 | none | — | 84+ | Stable |
| 168 | 46/F | Resp | 1.5 | BU-Cy 4 | CsA + MTX | BM | 0 | none | 6 | 82+ | CR |
| 215 | 53/M | Refr | 3.4 | TBI + Cy + MEL | T depletion | BM | 0 | none | 5 | 37 | Relapse |
| 231 | 30/F | Resp | 1.3 | TBI + Cy + MEL | T depletion | BM | 0 | none | 3 | 46+ | CR |
| 239 | 47/F | Resp | 1.6 | TBI + Cy + MEL | CsA + MTX | PB | 0 | limited | 2 | 45+ | CR |
| 254 | 47/M | Refr | 3.1 | TBI + Cy + MEL | CsA + MTX | PB | 0 | limited | 3 | 36+ | CR |
| 260 | 43/F | Resp | 1.1 | TBI + Cy + MEL | CsA + MTX | PB | 1 | none | Already in CR | 36+ | CR |
| 275 | 47/M | Refr | 2.9 | TBI + Cy + MEL | CsA + MTX | PB | 0 | extensive | 6 | 30+ | CR |
| 304 | 33/F | Resp | 1.2 | TBI + Cy + MEL | CsA + MTX | BM | 0 | none | Already in CR | 18+ | CR |
| 306 | 54/F | Resp | 1.4 | TBI + Cy + MEL | CsA + MTX | PB | 2 | extensive | 2 | 12 | CR |
| UPN . | Age/sex . | Status at allo SCT . | β2M (mg/L) . | Conditioning . | GVHD prophylaxis . | Source of SC . | GVHD . | Time to CR, mo . | Survival, mo . | Latest disease status . | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute . | Chronic . | ||||||||||
| 15 | 35/F | Resp | 1.7 | TBI + Cy + MEL | CsA | BM | 1 | limited | 12 | 188+ | CR |
| 95 | 49/F | Resp | 1.9 | BU-Cy 4 | T depletion | BM | 0 | none | 3 | 98+ | CR |
| 116 | 37/F | Resp | 2.1 | BU-Cy 4 | CsA + MTX | BM | 1 | limited | 3 | 84+ | CR |
| 142 | 36/F | Resp | 1.4 | BU-Cy 4 | CsA + MTX | BM | 0 | none | — | 84+ | Stable |
| 168 | 46/F | Resp | 1.5 | BU-Cy 4 | CsA + MTX | BM | 0 | none | 6 | 82+ | CR |
| 215 | 53/M | Refr | 3.4 | TBI + Cy + MEL | T depletion | BM | 0 | none | 5 | 37 | Relapse |
| 231 | 30/F | Resp | 1.3 | TBI + Cy + MEL | T depletion | BM | 0 | none | 3 | 46+ | CR |
| 239 | 47/F | Resp | 1.6 | TBI + Cy + MEL | CsA + MTX | PB | 0 | limited | 2 | 45+ | CR |
| 254 | 47/M | Refr | 3.1 | TBI + Cy + MEL | CsA + MTX | PB | 0 | limited | 3 | 36+ | CR |
| 260 | 43/F | Resp | 1.1 | TBI + Cy + MEL | CsA + MTX | PB | 1 | none | Already in CR | 36+ | CR |
| 275 | 47/M | Refr | 2.9 | TBI + Cy + MEL | CsA + MTX | PB | 0 | extensive | 6 | 30+ | CR |
| 304 | 33/F | Resp | 1.2 | TBI + Cy + MEL | CsA + MTX | BM | 0 | none | Already in CR | 18+ | CR |
| 306 | 54/F | Resp | 1.4 | TBI + Cy + MEL | CsA + MTX | PB | 2 | extensive | 2 | 12 | CR |
SC indicates stem cells; Resp, responsive; Refr, refractory; TBI, total body irradiation; Cy, cyclophosphamiole; MEL, high-dose melphalan; BU, busulfan; CsA, cyclosporine A; MTX, methotrexate; BM, bone marrow; PB, peripheral blood.